(Circulation. 1999;99:3315-3321.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Urokinase Receptor (uPAR, CD87) Is a Platelet Receptor Important for Kinetics and TNF-Induced Endothelial Adhesion in Mice
From the Departments of Pathology (P.F.P., C.V., Y.D., D.B., C.B.) and Pediatrics (C.B.), University of Geneva, and the WHO-IRTC, Institute of Biochemistry, University of Lausanne (F.T.-C.), Switzerland.
Correspondence to Pierre F. Piguet, MD, Department of Pathology, 1 rue M. Servet, CMU, 1211 Geneva, Switzerland. E-mail pierre.piguet{at}medecine.unige.ch
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Urokinase plasminogen activator receptor (uPAR, CD87) is a widely distributed 55-kD, glycoprotein I–anchored surface receptor. On binding of its ligand uPA, it is known to increase leukocyte adhesion and traffic. Using genetically deficient mice, we explored the role of uPAR in platelet kinetics and TNF-induced platelet consumption.
Methods and Results—Anti-uPAR antibody stained platelets from normal (+/+) but not from uPAR-/- mice, as seen by fluorescence-activated cell sorter analysis. 51Cr-labeled platelets from uPAR-/- donors survived longer than those from +/+ donors when injected into a +/+ recipient. Intratracheal TNF injection induced thrombocytopenia and a platelet pulmonary localization, pronounced in +/+ but absent in uPAR-/- mice. Aprotinin, a plasmin inhibitor, decreased TNF-induced thrombocytopenia. TNF injection markedly reduced the survival and increased the pulmonary localization of 51Cr-labeled platelets from +/+ but not from uPAR-/- donors, indicating that it is the platelet uPAR that is critical for their response to TNF. As seen by electron microscopy, TNF injection increased the number of platelets and polymorphonuclear neutrophils (PMNs) in the alveolar capillaries of +/+ mice, whereas in uPAR-/- mice, platelet trapping was insignificant and PMN trapping was slightly reduced. Platelets within alveolar capillaries of TNF-injected mice were activated, as judged from their shape, and this was evident in +/+ but not in uPAR-/- mice.
Conclusions—These results demonstrate for the first time the critical role of platelet uPAR for kinetics as well as for activation and endothelium adhesion associated with inflammation.
Key Words: platelets • tumor necrosis factor • plasminogen activators
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Platelets are essential for hemostasis. After damage of a blood vessel, they bind to the exposed basement membrane by use of several adhesion molecules, where they become activated and trigger the hemostatic cascade. During activation, platelets change their shape and their expression of surface molecules and eventually release their granular content.1
In addition, platelets also bind to the endothelium, a phenomenon frequently observed in vivo in association with various types of inflammation,2 including fibrogenesis and atherosclerosis.3 Tumor necrosis factor (TNF), the cytokine recognized as the central mediator of inflammation, has been reported to promote platelet adhesion to venular endothelial cells and alveolar capillaries.4 5 6 7 However, the effects of TNF on platelet adhesion are variable, depending on the mode of administration. In the Shwartzman type of reaction, elicited by sequential TNF injections, platelet consumption, evidenced by thrombocytopenia, and trapping are associated with thrombosis.8 This platelet consumption is presumably due to the capacity of TNF to increase the production of tissue factor.9 In contrast, in the reaction elicited by a single intravenous (IV) injection of TNF, platelet consumption is to a large extent coagulation-independent, because it is not associated with fibrinogen consumption and is not attenuated by heparin.10 11 Our recent work indicates that TNF-induced thrombocytopenia is not exerted by a direct effect of TNF on platelets but rather by an effect on the TNF receptor 1 (TNFR1) of cells other than platelets, leading to the production of platelet agonist(s), which are immediately responsible for the thrombocytopenia.12 One of the agonists involved in the thrombocytopenia induced by a single IV injection of TNF is serotonin, released by mast cells.11 Because TNF is extremely pleiotropic, it is likely that its influence on platelets is mediated by several different molecules whose importance varies depending on the model and mode of administration. Platelet agonists are indeed numerous (see review in Reference 1313 ), and the list includes proteases such as thrombin, cathepsin, and plasmin.
We have been interested in the possible role of plasminogen activators (PAs) and plasmin in inflammation and have observed that in some cases, platelet consumption and trapping induced by TNF are attenuated in urokinase plasminogen activator–deficient (uPA-/-) mice.14 However, these results were difficult to interpret, because TNF does not raise the plasmatic activity of uPA. Recent reports concerning the role of uPA receptor (uPAR) in leukocyte migration have shown that uPA binding to this receptor can not only polarize proteolysis on the surface of leukocytes15 but also influence adhesion by plasmin-independent mechanisms.16 17 uPAR is widely distributed and has been described on leukocytes, endothelial cells, and megakaryocytes.18 19 20
In the present report, we explored the role of uPAR in platelet kinetics as well as in platelet localization elicited by a single intratracheal (IT) injection of TNF in genetically deficient mice. We found that uPAR is expressed on platelets and that it has a profound effect on platelet kinetics as well as on TNF-induced platelet activation and endothelium adhesion.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mice
C57BL/6J (normal, +/+) and uPA-/-, tissue PA (tPA)-/-, and uPAR-/- genetically deficient mice isolated on the C57BL/6x129 background21 22 were obtained from P. Carmeliet, Belgium, and bred in our animal facility.
Bleeding Time and Platelet Aggregation
Bleeding time was recorded after a 2-mm cut on the
tail.23 Platelet microaggregation in whole blood was
performed as described elsewhere.24
Mouse Recombinant TNF
Mouse recombinant TNF-
(TNF) was a kind gift from B. Allet,
Glaxo IMB, Geneva. TNF or its saline control was injected IV in a
volume of 0.1 mL in the retro-orbital sinus or IT, also in a volume of
0.1 mL. In the latter case, mice were anesthetized with Ethrane
(Abbot No. 9406, Enflurane), the trachea was briefly exposed, the
reagent was injected, and the wound was closed with a clip.
Blood Isolation, Platelet Isolation, and 51Cr
Labeling
Donor mice were pretreated with heparin (5 U IM), and blood was
withdrawn from the retro-orbital plexus in heparinized capillaries and
diluted 1:3 in acid citrate dextrose (ACD). Blood elements were counted
in a Sysmex cell counter (Tao Medical).
Platelets were isolated by differential centrifugations in 10-mL graduated tubes at room temperature: ie, 5 minutes of centrifugation at 1000g to harvest the platelet-rich plasma and 10 minutes of centrifugation at 2800g to harvest the platelets. For 51Cr labeling, platelets were manipulated in ACD supplemented with mouse plasma (1%) as described.25 The preparation was examined in a hemocytometer to evaluate leukocyte or red blood cell (RBC) contaminants, which were always <10-4. Platelets (4x109 to 10x109/0.1 mL) were incubated at room temperature with 51Cr (0.1 mCi, The Radiochemical Center Amersham) for 2 hours. Platelets were then washed in ACD and counted. In different experiments, the labeling obtained ranged between 0.3 and 0.9 cpm/platelet depending on the age of the 51Cr batch. In 5 different experiments, the labeling obtained for platelets of +/+ or uPAR-/- donors was similar. Platelets were diluted with saline in order to inject 5x104 to 10x104 cpm/recipient mouse into the retro-orbital sinus.
Antibodies and Flow Cytometry
A rabbit anti-uPAR polyclonal antibody was provided by H.
Solberg.18 Rabbit IgG was detected by a
fluorescein-labeled goat anti-rabbit IgG. Platelets
(2x106/0.1 mL) were suspended in ACD added with
BSA (0.1%). Platelets were incubated in 0.1 mL for 45 minutes at
room temperature with normal goat serum (1% final concentration) and
subsequently with the specific or nonimmune rabbit IgG (50 µg/mL).
They were then washed 3 times by centrifugation for 10
minutes at 2800g and incubated with a FITC-labeled goat
anti-rabbit IgG (1 µg) and washed again. The platelet suspension
was examined with a FACScan flow cytometer (Becton Dickinson). Analytic
gates were set around platelets by looking at side (SSC) and
forward (FSC) angle light scatter in arithmetic acquisition mode.
Platelets were thus distinguished from larger or smaller elements,
such as RBCs (or leukocytes) and microvesicles, respectively.
Evaluation of Platelet and PMN Trapping in the Alveolar
Capillaries
Mice were anesthetized by an injection of pentobarbital
sodium (1.5 mg in 0.1 mL IP), and the abdominal aorta was
opened. The thorax was opened, and the lung was fixed by IT
instillation of glutaraldehyde (2% in 0.1 mol/L
cacodylate buffer, pH 7.0) and processed for embedding in epoxy resin.
A section was taken in the left lobe, across the hilum. Thin sections
were prepared from 2 blocks per mouse from the parenchyma. Thin
sections were examined with a Philips 400 electron microscope (EM) at
60 kV. Cells within alveolar capillaries were examined and RBCs,
platelets, and PMNs counted. On each block, 
100 RBCs were
counted. RBCs were used as a neutral indicator of blood stasis, and
sequestration was evaluated by the platelet/RBC and PMN/RBC
ratios.
To evaluate platelet activation, we measured the largest and
smallest platelet diameters on EM micrographs at 6000- to
12 000-fold magnification. Twenty or more
intracapillary platelets were examined for each
mouse. Nonactivated platelets are disk-shaped, and the
majority of sections thus appear as ellipses, with a ratio between the
largest and smallest diameters of 
3, as described
elsewhere.26 During the early phase of activation, they
become more spherical,1 and sections appear as circles,
with the ratio between the large and small diameters approaching 1.
This ratio was used as an "index of eccentricity" to evaluate
platelet activation.
Statistical Evaluation
Groups of values were compared by the nonparametric
Mann-Whitney U test.27
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
uPAR Is Expressed on Platelets
Platelets from +/+ or uPAR-/- mice were incubated with a rabbit anti-mouse uPAR antibody or with nonimmune rabbit IgG as a control. The fluorescence intensity obtained with a nonimmune rabbit IgG was similar for either type of platelet, whereas the anti-uPAR IgG shifted the peak of fluorescence intensity in +/+ but not in uPAR-/- platelets (Figure 1
).
|
Effect of uPAR Deficiency on Platelet Counts, Bleeding Time,
and Platelet Aggregation In Vitro
Platelet counts are known to be the most variable of the
blood elements. In normal mice, we observed values ranging between
850x103 and 1300x103
platelets/µL of blood from the retro-orbital sinus in different
experiments. Counts in +/+ and uPAR-/- were
within that range.
The tail bleeding time is influenced by defects in both coagulation and platelet function.23 In anesthetized mice at room temperature, the bleeding time was 15±4 minutes for either +/+ or uPAR-/- mice.
Platelet aggregation in response to thrombin in a whole-blood assay was similar for the blood of +/+ and uPAR-/- donors (not shown).
Role of uPAR in Platelet Survival
To explore more directly the role of platelet uPAR, we
compared the circulation of 51Cr-labeled
platelets from +/+ or uPAR-/- donors
injected into isogenic +/+ hosts. As seen in Figure 2, platelets from
uPAR-/- donors survived longer than those from
+/+ donors in a normal +/+ recipient. In Figure 2, the survival
was expressed in percentage of the injected cpm. Platelet
collection and manipulation involve the risk of eliciting some
platelet activation that might, after injection, result in an
immediate elimination from the circulation. To deal with this possible
bias, we also used the cpm measured in 0.05 mL of blood 0.5 hours after
injection as 100% and expressed the following values in % of this
starting point, and the figure was similar to that shown in Figure 2A. Thus, whatever the mode of evaluation, a significant
difference was evident between platelets from +/+ and
uPAR-/- donors in 5 different experiments.
|
The platelet population might contain tiny contaminants of leukocytes or RBCs (<1/10 000), which might contribute some radiation to the platelet population. To evaluate whether this contaminant can bias the survival evaluation, the platelet population was treated with thrombin in vitro immediately before platelet injection. In this case, the radiation detectable in the circulation 1 hour after injection was <1/104 of the injected radiation, indicating that the injected radiation was essentially carried by thrombin-responsive elements.
Because uPAR is expressed in endothelial cells, we also
explored the role of the host uPAR in platelet survival. As seen in
Figure 2B
, platelets from +/+ donors survive much longer in
uPAR-/- than in +/+ recipients. These results
indicate that both the host and the platelet uPAR contribute to
reduce the platelet life span.
TNF-Induced Thrombocytopenia in Aprotinin-Treated Mice and in uPA-,
tPA-, and uPAR-Deficient Mice
Administration of aprotinin (500 µg IV) significantly
(P<0.05) attenuated the thrombocytopenia induced by an IT
instillation of TNF; 6 hours after TNF injection, the platelet
counts were 980±90, 510±70, and 720±120 for controls,
saline/TNF-treated, and aprotinin/TNF-treated mice, respectively
(mean±SD, n=6).
The thrombocytopenia induced by an IT instillation of TNF was explored
in uPAR-deficient mice. As can be seen in a
representative experiment (Figure 3), the injection of TNF resulted in a
decrease in platelet counts from 1100x103
down to 650x103/µL, resulting in a loss of
40% of the circulating platelets in +/+ mice 6 hours later,
whereas in the uPAR-/-, the loss was on the
order of 20%. Injection of saline IT (and the necessary surgery)
raised the platelet counts, as seen 6 hours after injection (Figure 3). TNF-induced thrombocytopenia was also attenuated in
uPA-/- but not in
tPA-/- mice (not shown).
|
Effect of TNF on the Survival and Pulmonary Localization of
Labeled Platelets From +/+ or uPAR-/- Donors
Labeled platelets from +/+ or
uPAR-/- donors were transferred into +/+
recipients, which were subsequently injected with saline or TNF IT. As
evident by the radiation measured in the blood 4 hours after IT
injection, TNF markedly reduced the survival of platelets from +/+
donors, whereas it had no significant effect on platelets from
uPAR-/- donors (Figure 4).
|
Concomitantly, injection of TNF significantly increased the
pulmonary localization of labeled platelets from +/+ but
not from uPAR-/- donors (Figure 4).
Evaluation by EM of TNF-Induced Platelet and PMN Trapping in
the Alveolar Capillaries: Effect of uPAR on Platelet Activation
and Trapping
IT instillation of TNF (10 µg) markedly increased the number of
platelets and polymorphonuclear neutrophils (PMNs) within the
alveolar capillaries, as seen by EM 4 hours after injection (Figure 5). At that time
(Table), the number of platelets and
PMNs in the capillaries from +/+ mice was increased 3- to 4-fold
compared with the saline-injected controls. The relative frequency of
platelets was also markedly increased, from 0.1 and 0.07 for the
blood of the retro-orbital sinus of saline- and TNF-injected mice,
respectively, up to 0.98 in the alveolar capillaries. Injection of
saline itself (and the necessary surgery) also increased the number of
PMNs and platelets within the alveolar capillaries compared with
untreated controls (Table). In uPAR-/-
mice, TNF still increased the number of PMNs, whereas it had no
significant effect on platelet localization.
|
|
During activation, platelets loose their disk shape, become more
spherical, and produce pseudopodia.1 In the
saline-injected controls, the majority of platelets are presumably
in transit, and their eccentricity was accordingly 3, similar to
that seen in nonactivated platelets26
(Table and Figure 5). In TNF-injected +/+ mice, the
eccentricity was significantly decreased, indicating that platelets
are in an early phase of activation. In uPAR-/-
mice, the change in eccentricity was not significant.
Thus, within the alveolar capillaries of TNF-injected +/+ mice, there
was an increase of both the relative number of platelets and their
state of activation. As seen in Figure 5, platelet trapping
is not associated with contact with the basement membrane due to severe
endothelial damage or with the presence of fibrin.
Platelet-endothelium contacts were not frequently
observed in the plane of section. However, in rare micrographs,
platelets with pseudopodia sectioned within their axes were
observed, and these manifested at their extremity an area of intimate
contact with the endothelium (Figure 5C).
Because the number of pseudopodia per activated platelet is
small (2 to 4 per platelet, as seen by scanning EM of lightly
activated platelets in vitro), the probability of seeing a
pseudopodium sectioned along its axis by transmission EM is very low.
Thus, the rarity of these events on transmission EM does not exclude
the possibility that they are important for platelet binding.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present report, we provide evidence that uPAR (CD87) is an important receptor for platelet kinetics, activation, and endothelium binding associated with inflammation.
Using a rabbit anti-mouse uPAR antibody, we detected the uPAR on mouse platelets by fluorescence-activated cell sorter (FACS) analysis. A polyclonal antibody might raise doubt concerning the nature of the product recognized, but because there was a clear difference in the fluorescence intensity obtained with platelets from +/+ and uPAR-/- donors, this indicates that a product of the uPAR gene must be present on platelets. In humans, the uPAR and its mRNA have been detected in megakaryocytic cells.20
The regulation of platelet number and platelet kinetics in mice or humans is incompletely understood (eg, see review in Reference 2828 ). Platelet number is regulated in part by platelet production, ie, the growth of megakaryocytes, for which thrombopoietin appears to be the most important factor.29 On the other hand, cytokines such as TNF reduce platelet life span12 and might therefore play a role in platelet kinetics in normal mice, because this cytokine or its messenger RNA is detectable in normal individuals.30 The present report provides evidence that both platelet and host uPARs contribute to reduce the survival of platelets in the circulation. It remains to be explored whether platelet production is also modified in uPAR-/- mice.
TNF exerts a variety of effects on platelets that vary depending on the mode of administration. The present work was performed with single local (IT) TNF injection, a model that has the advantage, compared with IV injection, that the site of platelet consumption is localized and can therefore be examined directly. This TNF-induced thrombocytopenia was attenuated in uPAR-/- mice and in uPA-/- mice, but not in tPA-/- mice. It was also attenuated by the plasmin antagonist aprotinin, which suggests that plasmin contributes to this thrombocytopenia. In vitro, aprotinin has been reported to decrease platelet-endothelium adhesion.31
The functional importance of the uPAR, and more precisely of the
platelet uPAR, was documented directly by the comparison of the
TNF-induced localization of labeled platelets transferred in +/+
recipients. Platelets from uPAR-/- donors,
when present in +/+ recipients, were indeed unable to respond to a
local TNF injection, in contrast to those of +/+ donors (Figure 4). Because the uPAR is present on a wide variety of cells,
including endothelial cells, this type of experiment
demonstrates that it is the platelet uPAR that is critical for
TNF-induced localization.
After IT TNF instillation, thrombocytopenia is to a large extent due to platelet sequestration within the lung capillaries, which can be observed and quantified by EM. Platelets were not observed in a state of aggregation and degranulation or in association with fibrin, as is the case during hemostasis or the local Shwartzman reaction, elicited by 2 sequential TNF injections. Platelets not only were increased in number but also manifested evidence of activation, suggested by a more spherical shape. Rarely, pseudopodia connected to the platelet body were observed. These showed intimate contact with the endothelium, suggesting that they are the sites by which platelets are retained in the alveolar capillaries. In uPAR-/-, TNF had almost no effect on platelet activation and localization, indicating that this receptor is critical for both platelet activation and endothelium adhesion. Instillation of TNF also increased the number of PMNs within the capillaries, and this trapping was slightly attenuated in uPAR-/- mice, similar to what has been described previously in the mouse peritoneum.21 Other receptors have been documented to contribute to the TNF-induced adhesion of platelets to the venular endothelium, notably P-selectin,7 glycoprotein IIb/IIIa,32 and CD18.4
As a whole, our experiments demonstrate that the uPA-uPAR system is involved in platelet kinetics and in TNF-induced platelet-endothelium adhesion associated with inflammation. The platelet uPAR thus appears to be a platelet receptor whose function is restricted to inflammation, because its deficiency has no effect on hemostasis or platelet homotypic aggregation. The uPAR might act in part by the localization of plasmin, a platelet agonist, on the platelet surface, as suggested by the effect of aprotinin. In addition, uPAR might also act by increasing the function of other platelet integrins, notably ß1-, ß2-, and ß3-integrins, a mode of action documented for leukocytes.16 This latter possibility is suggested by the fact that uPA deficiency or aprotinin injections have less influence on platelet localization and trapping than the uPAR deficiency.
|
Acknowledgments |
|---|
This work was supported by grant 32-47284.96 from the Swiss National Science Foundation. We are grateful to D. Carmeliet for providing the deficient mice, to B. Imhof for a critical reading of the manuscript, and to D. Wohlwend in the Centre de Fluorographie du Centre Medical Universitaire for his help in the FACS analysis.
Received November 5, 1998; revision received March 23, 1999; accepted March 23, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Bithell TC. Blood coagulation. In: Lee RG, Bithell TC, Foerster J, Athens JW, Iukens JN, eds. Clinical Hematology. Philadelphia, Pa: Lea & Febiger; 1993:511–535.
2. Movat HZ, Cybulsky MI, Colditz IG, Chan MK, Dinarello CA. Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc. 1987;46:97–104.[Medline] [Order article via Infotrieve]
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]
4. Senaldi G, Piguet PF. Platelets play a role in the pathogenesis of the irritant reaction in mice. J Invest Dermatol. 1997;108:248–252.[Medline] [Order article via Infotrieve]
5.
Piguet PF, Kaufman S, Barazzone C, Muller M, Ryffel B,
Eugster HP. Resistance to bleomycin-induced fibrosis in TNF/LT
double deficient mice. Int J Exp Pathol. 1997;71:43–48.
6.
Barazzone C, Tacchini-Cottier F, Vesin C, Piguet PF.
Hyperoxia induces platelet activation and lung sequestration: an
event dependent upon TNF- and CD11a. Am J Respir
Cell Mol Biol. 1996;15:107–114.[Abstract]
7.
Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO,
Wagner DD. Platelet-endothelial interactions in
inflamed mesenteric venules. Blood. 1998;91:1318–1324.
8.
Piguet PF, Vesin C, Ryser JE, Senaldi G, Grau GE,
Tacchini-Cottier F. An effector role of platelets in the systemic
and local LPS-induced toxicity in mice, mediated by a CD11a/CD54
dependent interaction with the endothelium.
Infect Immun. 1993;61:4182–4187.
9.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran
RS, Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant
activity in cultured human vascular endothelium:
characterization and comparison with the actions of interleukin 1.
Proc Natl Acad Sci U S A. 1986;83:4533–4537.
10. Senaldi G, Piguet PF. Mortality and platelet depletion occur independently of fibrinogen consumption in murine models of tumor necrosis factor-mediated systemic inflammatory responses. Cytokine. 1998;10:382–389.[Medline] [Order article via Infotrieve]
11. Piguet PF, Vesin C, Guo J, Donati Y, Barazzone C. Role of mast cells and monoamines in the effects of TNF on platelet consumption and mortality in mice. Immunology. 1998;95:111–116.[Medline] [Order article via Infotrieve]
12.
Tacchini-Cottier F, Vesin C, Redard M, Buurman W,
Piguet PF. Role of TNF receptors I and II in TNF-induced platelet
consumption in mice. J Immunol. 1998;160:6182–6186.
13. Heffner JE, Repine JE. Platelets. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The Lung: Scientific Foundations. Philadelphia/New York: Lippincott-Raven; 1997:947–960.
14. Tacchini-Cottier F, Vesin C, Philippeaux MM, Belin D, Piguet PF. TNF-alpha induces platelet activation and consumption in vivo, a process involving urokinase and plasminogen. Eur Cytokine Netw. 1996;7:594. Abstract.
15. Vassalli J, Sappino A, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067–1072.
16. Chapman HA. Plasminogen activators, integrins and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997;9:714–724.[Medline] [Order article via Infotrieve]
17.
May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA,
Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment
via beta-2 integrins in vivo. J Exp Med. 1998;188:1029–1037.
18. Solberg H, Lober D, Ploug M, Ronne E, Behrendt N, Dano K, Hoyer-Hansen G. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Biochem. 1992;205:451–458.[Medline] [Order article via Infotrieve]
19. Barnathan ES. Characterization and regulation of the urokinase receptor of human endothelial cells. Fibrinolysis. 1992;6:1–9.
20. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost. 1997;77:540–547.[Medline] [Order article via Infotrieve]
21.
Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romer J,
Solberg H, Ellis V, Dano K, Degen JL. The receptor for urokinase-type
plasminogen activator is not essential for
mouse development or fertility. J Biol Chem. 1995;270:16886–16894.
22. Dewerchin M, Van Nuffelen A, Wallays G, Bouché A, Moons L, Carmeliet P. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest. 1996;97:870–878.[Medline] [Order article via Infotrieve]
23. Dejana E, Villa S, de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost. 1982;48:108–111.[Medline] [Order article via Infotrieve]
24. Menys VC, Belcher PR, Noble MIM, Evans ED, Drossos GE, Pillai R, Westaby S. Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined using optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man. Thromb Haemost. 1994;72:511–518.[Medline] [Order article via Infotrieve]
25.
ICSH panel. Recommended method for indium-111
platelet survival studies. J Nucl Med. 1988;29:564–566.
26. Stenberg PE, Levin J. Ultrastructural analysis of acute immune thrombocytopenia in mice: dissociation between alterations in megakaryocytes and platelets. J Cell Physiol. 1989;141:160–169.[Medline] [Order article via Infotrieve]
27. Mann HB, Whitney DR. On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.
28. Dale GL. Platelet kinetics. Curr Opin Haematol. 1997;4:330–334.[Medline] [Order article via Infotrieve]
29.
Kaushansky K. Thrombopoietin: the primary regulator of
platelet production. Blood. 1995;86:419–431.
30. Tovey MG, Content J, Gresser I, Gugenheim J, Blanchard B, Guymarho J, Poupart P, Gigou M, Shaw A, Fiers W. Genes for IFN-beta-2 (IL-6), tumor necrosis factor, and IL-1 are expressed at high levels in organs of normal individuals. J Immunol. 1988;141:3106–3110.[Abstract]
31. Royston BD, Royston D, Pearson JD. Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coagul Fibrinolysis. 1992;3:737–742.[Medline] [Order article via Infotrieve]
32. Li JM, Podolsky RS, Rohrer MJ, Cutler BS, Massie MT, Barnard MR, Michelson AD. Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. J Surg Res. 1996;61:543–548.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  F. Gueler, S. Rong, M. Mengel, J.-K. Park, J. Kiyan, T. Kirsch, I. Dumler, H. Haller, and N. Shushakova Renal Urokinase-Type Plasminogen Activator (uPA) Receptor but not uPA Deficiency Strongly Attenuates Ischemia Reperfusion Injury and Acute Kidney Allograft Rejection J. Immunol., July 15, 2008; 181(2): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Gondi, S. S. Lakka, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao Intraperitoneal Injection of a Hairpin RNA Expressing Plasmid Targeting Urokinase-Type Plasminogen Activator (uPA) Receptor and uPA Retards Angiogenesis and Inhibits Intracranial Tumor Growth in Nude Mice Clin. Cancer Res., July 15, 2007; 13(14): 4051 - 4060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Andonegui, S. M. Kerfoot, K. McNagny, K. V. J. Ebbert, K. D. Patel, and P. Kubes Platelets express functional Toll-like receptor-4 Blood, October 1, 2005; 106(7): 2417 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Peavy, K. B. Hubbard, A. Lau, R. B. Fields, K. Xu, C. J. Lee, T. T. Lee, K. Gernert, T. J. Murphy, and J. R. Hepler Differential Effects of Gq{alpha}, G14{alpha}, and G15{alpha} on Vascular Smooth Muscle Cell Survival and Gene Expression Profiles Mol. Pharmacol., June 1, 2005; 67(6): 2102 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kufrin, D. E. Eslin, K. Bdeir, J.-C. Murciano, A. Kuo, M. A. Kowalska, J. L. Degen, B. S. Sachais, D. B. Cines, and M. Poncz Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets Blood, August 1, 2003; 102(3): 926 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Piguet, C. Da Laperrousaz, C. Vesin, F. Tacchini-Cottier, G. Senaldi, and G. E. Grau Delayed Mortality and Attenuated Thrombocytopenia Associated with Severe Malaria in Urokinase- and Urokinase Receptor-Deficient Mice Infect. Immun., July 1, 2000; 68(7): 3822 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tarui, A. P. Mazar, D. B. Cines, and Y. Takada Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction J. Biol. Chem., February 2, 2001; 276(6): 3983 - 3990. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||